Evidence map›Paper›PMID 25477802›Full record

ArticleFrontiers in human neuroscience2014

Before it is too late: professional responsibilities in late-onset Alzheimer's research and pre-symptomatic prediction.

Silke Schicktanz, Mark Schweda, Jesse F Ballenger, Patrick J Fox, Jodi Halpern, Joel H Kramer, Guy Micco, Stephen G Post, Charis Thompson, Robert T Knight and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in human neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Changing definitions of disease: Transformations in the diagnostic criteria for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. The usual suspects: why techno-fixing dementia is flawed.Medicine, health care, and philosophy · 2017
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Silke SchicktanzDepartment of Medical Ethics and History of Medicine, University Medical Center Göttingen Göttingen, Germany.
Mark SchwedaDepartment of Medical Ethics and History of Medicine, University Medical Center Göttingen Göttingen, Germany ; Lichtenberg Kolleg, University of Göttingen Göttingen, Germany.
Jesse F BallengerHealth Administration Department, Drexel University Philadelphia, PA, USA.
Patrick J FoxInstitute for Health & Aging, University of California San Francisco, San Francisco, CA, USA.
Jodi HalpernUC Berkeley-UCSF Joint Medical Program, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Joel H KramerMemory and Aging Center, Sandler Neurosciences Center, University of California San Francisco, San Francisco, CA, USA.
Guy MiccoUC Berkeley-UCSF Joint Medical Program, School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Stephen G PostCompassionate Care & Bioethics, Stony Brook Medicine Stony Brook, NY, USA.
Charis ThompsonDepartment of Gender and Women's Studies, University of California Berkeley, Berkeley, CA, USA ; Department of Sociology, London School of Economics London, UK.
Robert T KnightDepartment of Psychology, University of California, Berkeley Berkeley, CA, USA ; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.
William J JagustUC Berkeley-UCSF Joint Medical Program, School of Public Health, University of California Berkeley, Berkeley, CA, USA ; Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of a wide array of molecular and neuroscientific biomarkers can provide the possibility to visualize the course of Alzheimer's disease (AD) at early stages. Many of these biomarkers are aimed at detecting not only a preclinical, but also a pre-symptomatic state. They are supposed to facilitate clinical trials aiming at treatments that attack the disease at its earliest stage or even prevent it. The increasing number of such biomarkers currently tested and now partly proposed for clinical implementation calls for critical reflection on their aims, social benefits, and risks. This position paper summarizes major challenges and responsibilities. Its focus is on the ethical and social problems involved in the organization and application of dementia research, as well as in healthcare provision from a cross-national point of view. The paper is based on a discussion of leading dementia experts from neuroscience, neurology, social sciences, and bioethics in the United States and Europe. It thus reflects a notable consensus across various disciplines and national backgrounds. We intend to initiate a debate on the need for actions within the researchers' national and international communities.

Indexed as

biomarkercultural diversitylate-onset Alzheimer’s dementiamedical ethicspublic engagementpublic health policyrecommendationsresearch participation

Identifiers

PMID25477802
PMCPMC4238325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.